Optimizing the antibacterial activity of a lead structure discovered by "SAR by MS" technology.
Jefferson
Elizabeth A
EA
Ibis Therapeutics, A Division of Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, USA. e.jeffers@isisph.com
Seth
Punit P
PP
Robinson
Dale E
DE
Winter
Dana K
DK
Miyaji
Alycia
A
Risen
Lisa M
LM
Osgood
Stephen A
SA
Bertrand
Myra
M
Swayze
Eric E
EE
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D005663:Furans / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D013058:Mass Spectrometry; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D010879:Piperazines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D012338:RNA, Ribosomal, 23S / Q000378:metabolism; D013329:Structure-Activity Relationship
D000900:Anti-Bacterial Agents; D005663:Furans; D010879:Piperazines; D012338:RNA, Ribosomal, 23S